Resumen
The increasing number of available anti-cancer drugs presents a challenge for oncologists, who must choose the most effective treatment for the patient. Precision cancer medicine relies on matching a drug with a tumor’s molecular profile to optimize the therapeutic benefit. However, current precision medicine approaches do not fully account for intra-tumoral heterogeneity. Different mutation profiles and cell behaviors within a single heterogeneous tumor can significantly impact therapy response and patient outcomes. Patient-derived avatar models recapitulate a patient’s tumor in an animal or dish and provide the means to functionally assess heterogeneity’s impact on drug response. Mouse xenograft and organoid avatars are well-established, but the time required to generate these models is not practical for clinical decision-making. Zebrafish are emerging as a time-efficient and cost-effective cancer avatar model. In this review, we highlight recent developments in zebrafish cancer avatar models and discuss the unique features of zebrafish that make them ideal for the interrogation of cancer heterogeneity and as part of precision cancer medicine pipelines.
| Idioma original | English |
|---|---|
| Número de artículo | 2288 |
| Publicación | International Journal of Molecular Sciences |
| Volumen | 24 |
| N.º | 3 |
| DOI | |
| Estado | Published - feb 2023 |
Nota bibliográfica
Publisher Copyright:© 2023 by the authors.
Financiación
This project was funded by the National Cancer Institute, R37CA227656 (J.S.B.); The ChadTough Defeat DIPG Foundation (J.S.B.); The Kentucky Pediatric Cancer Research Trust Fund (J.S.B); the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, UL1TR003107 to A.R. and UL1TR001998 to J.S.B. Stipend support for L.T.T. and A.R.M. was provided by the University of Kentucky’s Appalachian Career Training in Oncology (ACTION) Program, NCI R25CA221765 and the American Cancer Society Institutional Research Grant Diversity in Cancer Research Internship Supplement, IRG-19-140-31, respectively.
| Financiadores | Número del financiador |
|---|---|
| ChadTough Defeat DIPG Foundation | |
| Kentucky Pediatric Cancer Research Trust Fund | |
| National Institutes of Health (NIH) | UL1TR003107, UL1TR001998 |
| American Cancer Society-Michigan Cancer Research Fund | IRG-19-140-31 |
| National Childhood Cancer Registry – National Cancer Institute | R37CA227656, R25CA221765 |
| National Center for Research Resources | |
| National Center for Advancing Translational Sciences (NCATS) | |
| University of Kentucky |
ASJC Scopus subject areas
- Catalysis
- Molecular Biology
- Spectroscopy
- Computer Science Applications
- Physical and Theoretical Chemistry
- Organic Chemistry
- Inorganic Chemistry